Product category:
Nucleic acid sequencing and synthesis
News Release from: Tecan Group | Subject: Freedom Evo 150
Edited by the Laboratorytalk Editorial
Team on 30 March 2006
Tecan boosts RNA work in France
Researchers at Inserm's Institut Europeen de Chimie et Biologie (IECB), Bordeaux, have been using Freedom Evo to develop automated in vitro selection techniques for identifying and isolating aptamers
Aptamers are short, single-stranded oligonucleotides which specifically interact with high affinity proteins of interest for diagnostic procedures or in vivo imaging of, for example, viral RNA targets Manually performing the systematic evolution of ligands by exponential enrichment (Selex) method to identify aptamers is extremely labour-intensive; each round takes two to three days and eight to 15 repeats of each round are required to isolate the DNA/RNA candidates with the highest affinities for the targets
This article was originally published on Laboratorytalk on 29 May 2006 at 8.00am (UK)
Related stories
High throughput genotyping for complex diseases
Researchers at the Santiago de Compostela laboratory of the Centro Nacional de Genotipado in Spain are using a Freedom Evo 150 workstation to provide large scale genotyping and SNP analyses
CSI: Tecan, as workstation makes TV debut
A Tecan Freedom Evo 150 liquid handling workstation recently starred in a two-hour special episode of the long-running, forensic science-based television show CSI: Crime Scene Investigation.
Jean-Jacques Toulme's group at the IECB has automated the method using Tecan's Freedom Evo 150 workstation, equipped with robotic manipulator and liquid handling arms, as well as various peripheral separation, heating and shaking modules.
Fanny Vella, explained: " Automation allows us to complete two Selex rounds per day and we can run selections against at least four targets in parallel".
"We are currently trying to identify ligands that inhibit viral genes and are focusing on aptamers targeted to elements of viral RNA that are functionally involved in the expression of viral genes and, subsequently, development of the virus".
"Being able to control the expression of a viral gene without affecting the host's gene expression would provide an ideal way to prevent development of the virus".
"We will then be able to validate these molecules as targets of therapeutic interest for pathogenic viruses such as HIV and hepatitis C".
NB: This application has not been cleared in the US market.
• Tecan Group: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
